Navigation Links
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Date:9/19/2007

es of Dynavax's HBV vaccine; the other group received three doses of Engerix-B.

Dynavax reported in mid-July 2007, that an international Phase 3 trial in Europe and Canada had completed enrollment. Data from the pivotal Phase 3 trial plus lot-to-lot consistency trials will contribute to a safety database of approximately 4,000 subjects for a planned BLA submission in 2008. Dynavax's HBV vaccine is based on its proprietary immunostimulatory sequence (ISS) that specifically targets Toll-Like Receptor 9 (TLR9) to stimulate an innate immune response. Dynavax's HBV vaccine combines ISS with HBV surface antigen (HBsAg) and is designed to significantly enhance the level, speed and longevity of protection. Dynavax indicates that as a result of its acquisition of Rhein Biotech in April 2006, the company has secured manufacturing capabilities in Dusseldorf, Germany for producing both clinical and initial commercial quantities of the hepatitis B surface antigen component of the vaccine.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA(TM), a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo,
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
7. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
10. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
11. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 Pfenex ... its previously announced initial public offering of 8,333,333 shares of ... $6.00 per share. All of the common stock was offered ... 30-day option to purchase up to 1,250,000 additional shares of ... of common stock are traded on the NYSE MKT under ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Surgical Navigation Systems Market ... Systems) - Global Industry Analysis, Size, Share, Growth, Trends ... systems market was valued at USD 218.5 million in ... of 4.5% from 2014 to 2020, to reach an ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... Pa., April 14 Consumers who,purchased raw milk ... after March 18 should discard it immediately due ... Dennis Wolff,said today., Raw milk is milk ... selling raw milk must be permitted and have ...
... cisplatin observed in ovarian carcinoma xenografts, DUBLIN, ... ), a pharmaceutical company dedicated to the discovery, ... and,hematological malignancies, today announced as part of a ... that S-110, its DNA,methyltransferase inhibitor, improves in vivo ...
Cached Medicine Technology:SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 2SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 3
(Date:7/30/2014)... 30, 2014 The San Diego personal injury ... are announcing that they are now offering free case reviews ... asbestos exposure. , “Symptoms of asbestos exposure can take ... toxin 30 plus years ago may just now be suffering ... Law Office of Melinda J. Helbock A.P.C. “We want people ...
(Date:7/30/2014)... Connecticut (PRWEB) July 30, 2014 Pain ... new magnetic sports bracelet for pain relief and improved ... strength carbonized titanium embedded in a silicone core that ... also has Germanium and is embedded with scalar energy ... bracelet. , “Pain Free Living has 12 years experience ...
(Date:7/30/2014)... Nuanced Media, a specialist in web design and digital ... Web Design Trends of 2014. The web design trends ... and the medical web design industry throughout the year. , ... grows. Therefore it is important for existing practices and new ... New trends are defined by advances in the medical industry ...
(Date:7/29/2014)... Cucamonga, CA (PRWEB) July 29, 2014 Paul ... Ways to Make More Money in 30 Days” E-book. The ... anyone can use to make extra cash. Examples include downloading ... utilizing unique free websites that help people monetize the assets ... and even unused items they can find in their garage. ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... Cause of Death in Long-Term Survivors of Hereditary Retinoblastoma ... increased risk of death due to a second cancer, ... a very rare cancer of the eye that affects ... of retinoblastoma are at risk of subsequent malignancies but ...
... Hear Public Comments on Comparative Effectiveness Research ... 7 The Federal Coordinating Council for ... listening session on April 14, 2009, in ... comment regarding comparative effectiveness research and the ...
... to worse outcomes , , TUESDAY, April 7 (HealthDay News) ... more likely to die or need a second heart ... according to the results of a U.S. study. , ... who received their first heart transplant at Children,s Hospital ...
... but activity is safe and should be urged, expert says, ... of moderate exercise will not harm people with heart failure ... has found. , That admittedly tepid conclusion comes from a ... at 82 centers in the United States, Canada and France. ...
... Mayo Clinic researchers have discovered the mechanisms behind two ... that may ultimately allow investigators to benchmark progression of ... findings appear in the current online issue of ... by Edward Leof, Ph.D. , Mayo Clinic biochemist, ...
... of Global Breast Cancer Movement Continues Unprecedented Investment ... Committed to caring for those coping with ... of the disease, Susan G. Komen for the ... announced $60 million in research grants to U.S. ...
Cached Medicine News:Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Federal Coordinating Council on Comparative Effectiveness Research to Hold Public Listening Session in Washington, DC 2Health News:Heart Transplant Failures More Likely in Poor, Minority Kids 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3Health News:Mayo researchers discover mechanism of cell type-specific signaling in tumor development 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 3Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 4Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 5
... continuous low-flow nebulizer performance. Patented auxiliary ... allows for optimal medication and Heliox ... OMNI~NEB takes on severe asthma, COPD ... critical care situations. Configure with a ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
... Mouthpiece 7FT O 2 Tubing Tee Adapter ... are designed to provide maximum aerosol quality and ... fast treatment time. Each of these high-efficiency nebulizers ... vent seal adapter for use with your ventilator ...
Nebulizer Custom Kit...
Medicine Products: